Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
PEAK's team handles the prior authorization process and works directly with your insurance to determine coverage before treatment begins
Why Many Labs Prefer High-Purity BPC-157 When a peptide is still in the research-only stage, the quality of the material has an outsized impact on the value of the data that labs collect
This happens through three mechanisms: dietary modification (reducing sulfur-containing substrate), competitive exclusion (introducing beneficial bacteria that outcompete SRB), and environmental optimization (maintaining conditions that favor beneficial bacteria over SRB)
Diagnosis and risk stratification of NAFLD should be led by your GP, typically using blood tests and scoring systems such as FIB-4 or the Enhanced Liver Fibrosis (ELF) test, in line with NICE guidance
Eligible self-pay patients can currently access the medication starting at $149 per month for select doses through April 15, 2026
Hepatitis C virus (HCV) infection associated with chronic hepatitis is one of the most prevalent causes of liver-related mortality and morbidity worldwide.1 HCV infection is a risk factor for hepatocellular carcinoma and cirrhosis.2 Patients with posttransfusional hepatitis C might develop cirrhosis after an average of 21 years and hepatocellular carcinoma after an average of 29 years.3 Because the most serious consequences of HCV appear several years after infection acquisition, to improve outcomes and optimize resources, it is important to identify HCV-infected patients who are at high risk for progressive liver diseases and who may benefit from early therapeutic intervention
US$ 29.29
US$ 23.31
US$ 27.82
